References
Key articles
Fakhouri F, Zuber J, Frémeaux-Bacchi V, et al. Haemolytic uraemic syndrome. Lancet. 2017 Aug 12;390(10095):681-96. Abstract
Banatvala N, Griffin PM, Greene KD, et al. The United States national prospective hemolytic uremic syndrome study: microbiologic, serologic, clinical and epidemiologic findings. J Infect Dis. 2001 Apr 1;183(7):1063-70. Abstract
Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005 Mar 19-25;365(9464):1073-86. Abstract
Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000 Jun 29;342(26):1930-6.Full text Abstract
McKee RS, Schnadower D, Tarr PI, et al; Pediatric Emergency Medicine Collaborative Research Committee and Pediatric Emergency Research Canada. Predicting hemolytic uremic syndrome and renal replacement therapy in Shiga toxin-producing Escherichia coli-infected children. Clin Infect Dis. 2020 Apr 10;70(8):1643-51.Full text Abstract
Loirat C, Fakhouri F, Ariceta G, et al; HUS International. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016 Jan;31(1):15-39. Abstract
Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic uremic syndrome. N Engl J Med. 1995 Aug 10;333(6):364-8. Abstract
Rathbone J, Kaltenthaler E, Richards A, et al. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. 2013 Nov 4;3(11):e003573.Full text Abstract
Reference articles
1. Keir LS, Saleem MA. Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol. 2014 Oct;29(10):1895-902. Abstract
2. Cody EM, Dixon BP. Hemolytic uremic syndrome. Pediatr Clin North Am. 2019 Feb;66(1):235-46. Abstract
3. Yan K, Desai K, Gullapalli L, et al. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol. 2020 Mar 12;12:295-305.Full text Abstract
4. Nester CM, Andreoli SP. Renal involvement in children with HUS. In: Avner E, Harmon W, et al. (eds). Pediatric nephrology. 7th ed. Berlin, Heidelberg: Springer-Verlag; 2016.
5. Fakhouri F, Zuber J, Frémeaux-Bacchi V, et al. Haemolytic uraemic syndrome. Lancet. 2017 Aug 12;390(10095):681-96. Abstract
6. Atkinson JP, Liszewski MK, Richards A, et al. Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue. Ann NY Acad Sci. 2005 Nov;1056:144-52. Abstract
7. Banatvala N, Griffin PM, Greene KD, et al. The United States national prospective hemolytic uremic syndrome study: microbiologic, serologic, clinical and epidemiologic findings. J Infect Dis. 2001 Apr 1;183(7):1063-70. Abstract
8. Bell BP, Goldoft M, Griffin PM, et al. A multistate outbreak of Escherichia coli 0157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA. 1994 Nov 2;272(17):1349-53. Abstract
9. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005 Mar 19-25;365(9464):1073-86. Abstract
10. Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000 Jun 29;342(26):1930-6.Full text Abstract
11. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005 Apr;16(4):1035-50.Full text Abstract
12. Adams N, Byrne L, Rose T, et al. Sociodemographic and clinical risk factors for paediatric typical haemolytic uraemic syndrome: retrospective cohort study. BMJ Paediatr Open. 2019 Dec 17;3(1):e000465.Full text Abstract
13. McKee RS, Schnadower D, Tarr PI, et al; Pediatric Emergency Medicine Collaborative Research Committee and Pediatric Emergency Research Canada. Predicting hemolytic uremic syndrome and renal replacement therapy in Shiga toxin-producing Escherichia coli-infected children. Clin Infect Dis. 2020 Apr 10;70(8):1643-51.Full text Abstract
14. Cochran JB, Panzarino VM, Maes LY, et al. Pneumococcus-induced T-antigen activation in hemolytic uremic syndrome and anemia. Pediatr Nephrol. 2004 Mar;19(3):317-21. Abstract
15. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998 Apr;53(4):836-44. Abstract
17. Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011 Sep 15;17(18):5858-66. Abstract
18. Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet. 1998 Oct 10;352(9135):1207-12. Abstract
19. Centers for Disease Control and Prevention. Reports of selected E. coli outbreak investigations. Dec 2021 [internet publication].Full text
20. Tabuchi A, Wakui T, Yahata Y, et al. A large outbreak of enterohaemorrhagic Escherichia coli O157, caused by low-salt pickled Napa cabbage in nursing homes, Japan, 2012. Western Pac Surveill Response J. 2015 Apr-Jun;6(2):7-11.Full text Abstract
21. Wikswo ME, Hall AJ, Centers for Disease Control and Prevention. Outbreaks of acute gastroenteritis transmitted by person-to-person contact - United States, 2009-2010. MMWR Surveill Summ. 2012 Dec 14;61(9):1-12.Full text Abstract
22. Dixon BP, Gruppo RA. Atypical hemolytic uremic syndrome. Pediatr Clin North Am. 2018 Jun;65(3):509-25. Abstract
23. Seaby EG, Gilbert RD. Thrombotic microangiopathy following haematopoietic stem cell transplant. Pediatr Nephrol. 2018 Sep;33(9):1489-500.Full text Abstract
24. Al-Nouri ZL, Reese JA, Terrell DR, et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015 Jan 22;125(4):616-8.Full text Abstract
25. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2001 Sep;8(5):286-93. Abstract
26. Bruel A, Kavanagh D, Noris M, et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1237-47.Full text Abstract
27. Fakhouri F, Scully M, Provôt F, et al. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood. 2020 Nov 5;136(19):2103-17.Full text Abstract
28. Thomas DE, Elliott EJ. Interventions for preventing diarrhea-associated hemolytic uremic syndrome: systematic review. BMC Public Health. 2013 Sep 3;13:799.Full text Abstract
29. Karch H, Janetzki-Mittmann C, Aleksic S, et al. Isolation of enterohemorrhagic Escherichia coli O157 strain from patients with hemolytic uremic syndrome by using immunomagnetic separation, DNA based methods and direct culture. J Clin Microbiol. 1996 Mar;34(3):516-9. Abstract
30. Xie J, Tarr GAM, Ali S, et al. Pigment visibility on rectal swabs used to detect enteropathogens: a prospective cohort study. J Clin Microbiol. 2019 Jun;57(6):e00213-19.Full text Abstract
31. Lee H, Kang E, Kang HG, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020 Jan;35(1):25-40.Full text Abstract
32. McCrae KR. Thrombocytopenia in pregnancy: differential diagnosis, pathogenesis and management. Blood Rev. 2003 Mar;17(1):7-14. Abstract
33. Slutsker L, Ries AA, Greene KD, et al. Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features. Ann Intern Med. 1997 Apr 1;126(7):505-13. Abstract
34. Cataland SR, Wu HM. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood. 2014 Apr 17;123(16):2478-84.Full text Abstract
35. Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int. 1995 Jul;48(1):2-19. Abstract
36. Gerber A, Karch H, Allerberger F, et al. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis. 2002 Aug 15;186(4):493-500. Abstract
37. Baccini V, Geneviève F, Jacqmin H, et al. Platelet counting: ugly traps and good advice. Proposals from the French-speaking Cellular Hematology Group (GFHC). J Clin Med. 2020 Mar 16;9(3):808.Full text Abstract
38. Kavanagh D, Richards A, Fremeaux-Bacchi V, et al. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2007 May;2(3):591-6. Abstract
39. Veyradier A, Obert B, Houllier A, et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001 Sep 15;98(6):1765-72. Abstract
40. Mannucci PM. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: much progress and many remaining issues. Haematologica. 2007 Jul;92(7):878-80. Abstract
41. Sevitt LH, Naish P, Baker LR, et al. The significance of microangiopathic haemolytic anaemia in accelerated hypertension. Br J Haematol. 1973 Apr;24(4):503-10. Abstract
42. Musio F, Bohen EM, Yuan CM, et al. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum. 1998 Aug;28(1):1-19. Abstract
43. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine (Baltimore). 1998 May;77(3):195-207. Abstract
44. Merrill JT, Asherson RA. Catastrophic antiphospholipid syndrome. Nat Clin Pract Rheumatol. 2006 Feb;2(2):81-9. Abstract
45. McCrae KR, Cines DB. Thrombotic microangiopathy during pregnancy. Semin Hematol. 1997 Apr;34(2):148-58. Abstract
46. Loirat C, Fakhouri F, Ariceta G, et al; HUS International. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016 Jan;31(1):15-39. Abstract
47. Bagga A, Khandelwal P, Mishra K, et al; Indian Society of Pediatric Nephrology. Hemolytic uremic syndrome in a developing country: consensus guidelines. Pediatr Nephrol. 2019 Aug;34(8):1465-82. Abstract
48. Michael M, Elliott EJ, Ridley GF, et al. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD003595.Full text Abstract
49. Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic uremic syndrome. N Engl J Med. 1995 Aug 10;333(6):364-8. Abstract
50. Hickey CA, Beattie TJ, Cowieson J, et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med. 2011 Oct;165(10):884-9.Full text Abstract
51. Ardissino G, Tel F, Possenti I, et al. Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics. 2016 Jan;137(1):e20152153. Abstract
52. Tarr PI, Neill MA. Escherichia coli O157:H7. Gastroenterol Clin North Am. 2001 Sep;30(3):735-51. Abstract
53. Siegler RL. The hemolytic uremic syndrome. Pediatr Clin North Am. 1995 Dec;42(6):1505-29. Abstract
54. Caletti MG, Lejarraga H, Kelmansky D, et al. Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome. Pediatr Nephrol. 2004 Oct;19(10):1148-52. Abstract
55. Van Dyck M, Proesmans W. Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol. 2004 Jun;19(6):688-90. Abstract
56. Imdad A, Mackoff SP, Urciuoli DM, et al. Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome. Cochrane Database Syst Rev. 2021 Jul 5;(7):CD012997.Full text Abstract
57. Centers for Disease Control and Prevention. E. coli (Escherichia coli). Resources for clinicians and laboratories. Dec 2014 [internet publication].Full text
58. Wong CS, Mooney JC, Brandt JR, et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis. 2012 Jul;55(1):33-41.Full text Abstract
59. Nelson JM, Griffin PM, Jones TF, et al. Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites. Clin Infect Dis. 2011 May;52(9):1130-2.Full text Abstract
60. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017 Nov 29;65(12):e45-80.Full text Abstract
61. Cimolai N, Morrison BJ, Carter JE. Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome. Pediatrics. 1992 Oct;90(4):616-21. Abstract
62. Bell WR, Braine HG, Ness PM, et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. N Engl J Med. 1991 Aug 8;325(6):398-403. Abstract
63. Siegler RL, Pavia AT, Christofferson RD. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics. 1994 Jul;94(1):35-40. Abstract
64. Rowe PC, Orrbine E, Lior H, et al. Risk of hemolytic uremic syndrome after sporadic Escherichia coli O157:H7 infection: results of a Canadian collaborative study. J Pediatr. 1998 May;132(5):777-82. Abstract
65. Upadhyaya K, Barwick K, Fishaut M, et al. The importance of nonrenal involvement in hemolytic-uremic syndrome. Pediatrics. 1980 Jan;65(1):115-20. Abstract
66. Grodinsky S, Telmesani A, Robson WL, et al. Gastrointestinal manifestations of hemolytic uremic syndrome: recognition of pancreatitis. J Pediatr Gastroenterol Nutr. 1990 Nov;11(4):518-24. Abstract
67. Rigamonti D, Simonetti GD. Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature. Eur J Pediatr. 2016 Dec;175(12):1927-31. Abstract
68. Benvenuto F, Guillen S, Marchiscio L, et al. Purtscher-like retinopathy in a paediatric patient with haemolytic uraemic syndrome: a case report and literature review. Arch Soc Esp Oftalmol (Engl Ed). 2021 Nov;96(11):607-10. Abstract
69. Mauras M, Bacchetta J, Duncan A, et al. Escherichia coli-associated hemolytic uremic syndrome and severe chronic hepatocellular cholestasis: complication or side effect of eculizumab? Pediatr Nephrol. 2019 Jul;34(7):1289-93. Abstract
70. Rathbone J, Kaltenthaler E, Richards A, et al. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. 2013 Nov 4;3(11):e003573.Full text Abstract
71. Menne J, Delmas Y, Fakhouri F, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019 Apr 10;20(1):125.Full text Abstract
72. Pugh D, O'Sullivan ED, Duthie FA, et al. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev. 2021 Mar 23;(3):CD012862.Full text Abstract
73. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81.Full text Abstract
74. Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015 May;87(5):1061-73.Full text Abstract
75. Ferraris JR, Ramirez JA, Ruiz S, et al. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation. Pediatr Nephrol. 2002 Oct;17(10):809-14. Abstract
76. Barbour T, Scully M, Ariceta G, et al; 311 Study Group Members. Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney Int Rep. 2021 Jun;6(6):1603-13.Full text Abstract
77. Tanaka K, Adams B, Aris AM, et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol. 2021 Apr;36(4):889-98.Full text Abstract
78. ClinicalTrials.gov. Study of ravulizumab in children and adolescents with atypical hemolytic uremic syndrome (aHUS). NCT03131219. Apr 2022 [internet publication].Full text
79. ClinicalTrials.gov. Study of ALXN1210 in complement inhibitor treatment-naïve adult and adolescent participants with atypical hemolytic uremic syndrome (aHUS). NCT02949128. Mar 2022 [internet publication].Full text
80. Khandelwal P, Bagga A. Guidelines on hemolytic uremic syndrome by Indian Society of Pediatric Nephrology: key messages. Indian Pediatr. 2020 Aug 15;57(8):744-7.Full text Abstract
81. Strazdins V, Watson AR, Harvey B. Renal replacement therapy for acute renal failure in children: European guidelines. Pediatr Nephrol. 2004 Feb;19(2):199-207.Full text Abstract
82. NSW Government (Australia). Haemolytic uraemic syndrome (HUS) and shigatoxigenic E. coli infections (STEC) control guideline. Sep 2016 [internet publication].Full text
83. Public Health England. Shiga toxin-producing Escherichia coli: guidance, data and analysis. Oct 2018 [internet publication].Full text
84. Mody RK, Gu W, Griffin PM, et al. Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. J Pediatr. 2015 Apr;166(4):1022-9. Abstract
85. Sheth KJ, Swick HM, Haworth N. Neurological involvement in hemolytic-uremic syndrome. Ann Neurol. 1986 Jan;19(1):90-3. Abstract
86. Constantinescu AR, Bitzan M, Weiss LS, et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis. 2004 Jun;43(6):976-82. Abstract
87. Murgo A. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol. 1987 Jul;24(3):161-77. Abstract
88. Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol. 2001 Apr;113(1):58-64. Abstract
89. Kwaan HC, Gordon LI. Thrombotic microangiopathy in the cancer patient. Acta Haemat. 2001;106(1-2):52-6. Abstract
90. Ohali M, Shalev H, Schlesinger M, et al. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr Nephrol. 1998 Oct;12(8):619-24. Abstract
91. Rougier N, Kazatchkine MD, Rougier JP, et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol. 1998 Dec;9(12):2318-26. Abstract
92. Landau D. Shalev J, Levy-Finer G, et al. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr. 2001 Mar;138(3):412-7. Abstract
93. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Kidney Int. 2001 Sep;60(3):831-46. Abstract
94. Brandt JR, Fouser LS, Watkins LS, et al. Escherichia coli O157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr. 1994 Oct;125(4):519-26. Abstract
95. Tapper D, Tarr P, Avner E, et al. Lessons learned in the management of hemolytic uremic syndrome in children. J Pediatr Surg. 1995 Feb;30(2):158-63. Abstract
96. Brandt JR, Joseph MW, Fouser LS, et al. Cholelithiasis following Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Nephrol. 1998 Apr;12(3):222-5. Abstract
Use of this content is subject to our disclaimer